Business Wire

Verimatrix XTD Accessibility Abuse Detector™ Brings Expanded Android App Protections

Share

Regulatory News:

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced the general availability of its Verimatrix XTD Accessibility Abuse Detector™ service that builds upon its ongoing successful discoveries of notable Android security threats and provides much-needed GDPR protections.

Verimatrix XTD and its suite of cybersecurity solutions have been helping customers identify Android mobile app threats such as tampering and abuse of Android's accessibility feature for many years. However, the company has now enhanced its offerings by adding proactive capabilities leveraging AI and ML to detect keylogging, credit card data theft, and comprehensive anti-overlay attack protection. These vital capabilities fortify the protective shield built into mobile apps, ensuring Verimatrix XTD Accessibility Abuse Detector™ provides robust, multi-layered security against modern mobile app threats. With its innovative technology and commitment to staying ahead of bad actors, Verimatrix products combined with monitoring and threat investigation services provided by XTD Labs, helps customers safeguard their applications and protect their customers' sensitive data.

As an added benefit, the Verimatrix XTD Accessibility Abuse Detector™ feature, combined with all the other features and benefits included in its offerings helps customers address 9 out of 10 OWASP Top 10 Mobile Risks. The OWASP Mobile Security Project aims to educate developers and security teams on building secure mobile apps. Understanding mobile app risks helps avoid pitfalls and protect user data. The OWASP Mobile Security Testing Guide provides comprehensive security testing guidelines for iOS and Android apps. The Mobile Application Security Verification Standard offers development guidance and testing standards.

“Any opportunity to dramatically reduce the chance of personal information theft, account information breaches, misuse of login authentication, or credit card fraud is welcome,” said Tom Powledge, Head of Cybersecurity Business for Verimatrix. “Verimatrix XTD Accessibility Abuse Detector™ is a great feature because it proactively prevents overlay attacks, one of the more prevalent mobile app exploits we see in banking and financial services. It’s a real win for customers as they are able to suspend compromised app instances to avoid financial losses or credential theft."

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Verimatrix Investor:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com

Verimatrix Media:
Matthew Zintel
matthew.zintel@zintelpr.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DentalMonitoring Sets New Standard in Orthodontic Remote Monitoring With EU-MDR Certification14.6.2024 19:33:00 CEST | Press release

DentalMonitoring is proud to announce that the DentalMonitoring Software is now certified under the European Union Medical Device Regulation 2017/745 (EU MDR) and fulfills the requirements for CE marking as a class IIa medical device. European Medical Device Regulation 2017/745 (EU MDR) replaces the previous Medical Device Directive 93/42/EEC (MDD). EU MDR sets more rigorous requirements for clinical evaluation, risk management, post-market surveillance, and data collection on medical devices.(1) This landmark achievement underscores DentalMonitoring's commitment to advancing dental care through cutting-edge technology and rigorous regulatory compliance. Achieving this certification four years ahead of the deadline demonstrates DentalMonitoring's commitment to positioning itself as an innovative, serious, efficient, and safe player in the medical field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614842101/en/ DentalMo

Argonne and a Moroccan University Sign Agreement to Advance Green Energy Tech and Computing14.6.2024 15:24:00 CEST | Press release

The U.S. Department of Energy’s (DOE) Argonne National Laboratory and University Mohammed VI Polytechnic (UM6P) have signed a memorandum of understanding (MOU) to collaborate on key areas of mutual interest related to green energy technology and the nexus of water and energy. In a ceremony held at UM6P’s campus in Benguerir, the MOU was signed by Argonne Laboratory Director Paul Kearns and UM6P President Hicham El Habti. “We are excited to see what discoveries and innovations will result from our ongoing partnership,” said Kearns. ​“By working together, we’ll open new scientific frontiers for both our countries’ futures.” “Today marks a significant milestone in our journey towards sustainable innovation. The signing of this Memorandum of Understanding with Argonne National Laboratory underscores our commitment to advancing research and development in renewable energy, energy grids, and water management. Together, we aim to leverage our collective expertise to create transformative solu

MultiBank Group Recognized as Top BaFin-Regulated Forex Broker14.6.2024 14:33:00 CEST | Press release

MultiBank Group is thrilled to announce its recognition as a top BaFin-regulated forex broker by FXEmpire, a leading financial markets authority. This prestigious accolade highlights MultiBank Group's unwavering commitment to excellence, security, and innovation in the forex trading industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614306878/en/ Top BaFin regulated forex broker 2024 (Graphic: Business Wire) About BaFin: Regulating German Financial Markets BaFin, Germany's Federal Financial Supervisory Authority, oversees the country's banking, securities, and insurance sectors. It ensures fair and transparent operations in the forex and CFD markets by enforcing rigorous standards. Selection Methodology FXEmpire's methodology for selecting the best BaFin-regulated brokers includes: Regulation Verification: Ensuring each broker is BaFin-regulated, providing traders with high-level protection. Cost Efficiency: Brokers

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)14.6.2024 14:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia. Despite the impact TKIs have had in the treatment of patients with CML, there remains significant unmet need for patients whose disease is resistant or refractory to these therapies or who develop hard-to-treat mutations following these treatments. “Takeda has a long history of driving important treatment advances for patients, particularly those with hematological cancers facing treatment gaps,” said Teresa Bitetti, president of the Globa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye